By Kim Richters 

Germany's Merck KGaA (MRK.XE) said Tuesday that it signed a licensing agreement to grant Evotec SE (EVT.XE) access to its CRISPR genome-editing technology.

The German biotechnology company will use Merck's gene-editing technology to research, test and develop new drugs, the company said.

The science and technology company didn't comment on financial terms of the deal.


Write to Kim Richters at


(END) Dow Jones Newswires

November 12, 2019 08:38 ET (13:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.